Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation An update of existing recommendations;Umstellung von einem Calcineurin-Inhibitor auf eine Sirolimus-basierte Therapie nach Nierentransplantation: Eine Aktualisierung der bestehenden Konsensus-Empfehlungen

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 49, 2011, Pages 2554-2559

  Arns, W ^a   Budde, K ^b   Eitner, F ^c   Gwinner, W ^d   Hugo, C ^e   Pressmar, K ^f   Weimann, A ^g   Witzke, O ^h  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Chirurgische Klinik und Poliklinik II Transplantationsambulanz   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

calcineurin inhibitor toxicity; chronic allograft nephropathy; mTOR inhibitor; sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; RAPAMYCIN;

KIDNEY TRANSPLANTATION; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SUBSTITUTION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 82655189405     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1292822     Document Type: Review

References (62)

1. Altenburg A, Zouboulis CC. Current concepts in the treatment of recurrent aphthous stomatitis. Skin Therapy Lett: 2008; 13 1 4
2. ANZDATA The Australia and New Zealand Dialysis and Transplant Registry The 30th Annual Report 2007 Report Data to 2006. http://www.anzdata.org.au/v1/ report-2007.html
3. Arns W, Diekmann F. für die Mitglieder des Advsory Boards Rapamune Konsensus-Statement zu Umstellung und Therapieoptimierung nierentransplantierter Patienten mit Sirolimus Update 2005. Nieren- und Hochdruckkrankheiten: 2005; 34 551 555 (Pubitemid 43051921)
4. Boratyska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int: 2008; 21 605 608 (Pubitemid 351600070)
5. Bchler M, Lebranchu Y, Bnton M et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther: 2005; 78 34 42 (Pubitemid 40956929)
6. Budde K. et al. for the ZEUS Study Group Analysis of Renal Function in Everolimus/Enteric-Coated Mycophenolate Sodium Treated De Novo Renal Transplant Recipients after Calcineurin Inhibitor Withdrawal. Abstract #237 Am J Transplant: 2009; 5 259 259
7. Burdese M, Rossetti M, Guarena C et al. Sirolimus and ACE-inhibitors: a note of caution. Transplantation: 2005; 79 251 252
8. Campistol JM, Albanell J, Arns W et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies clinical guidance. Nephrol Dial Transplant: 2007; 22 (01) i36 i41 (Pubitemid 47073743)
9. Campistol JM, Cockwell P, Diekmann F et al. Practical recommendations for the early use of mTOR inhibitors (sirolimus) in renal transplantation. Transpl Int: 2009; 22 681 687
10. Campistol JM, de Fijter JW, Flechner SM et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant: 2010; 24 149 156
11. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol: 2006; 17 581 589
12. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation: 2004; 77 760 762 (Pubitemid 38366986)
13. Cattaneo D, Merlini S, Zenoni S et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant: 2005; 5 2937 2944 (Pubitemid 43923955)
14. Champion L, Stern M, Isral-Biet D et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med: 2006; 144 505 509 (Pubitemid 46780673)
15. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant: 2007; 7 714 717 (Pubitemid 46376460)
16. Dean PG, Lund WJ, Larson TS et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation: 2004; 77 1555 1561 (Pubitemid 38703037)
17. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant: 2004; 4 1869 1875 (Pubitemid 39434449)
18. Dittrich E, Schmaldienst S, Soleiman A et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int: 2004; 17 215 220 (Pubitemid 38758188)
19. Duerr M, Glander P, Diekmann F et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol: 2010; 5 703 708
20. Fachinformation Rapamune 0,5 mg/- 1 mg/- 2 mg PFIZER PHARMA GmbH: 01 2011
21. Guba M, Pratschke J, Hugo C. et al. for the SMART-Study Group Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin InhibitorBased Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. Transplantation: 2010; 90 175 183
22. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med: 2002; 8 128 135 (Pubitemid 34155123)
23. Hariharan S, McBride MA, Cherikh WS et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int: 2002; 62 311 318 (Pubitemid 34754077)
24. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol: 2009; 27 3822 3829
25. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell autonomous mechanism. Nature: 1999; 397 530 534
26. Hudes G, Carducci M, Tomczak P. et al. for the Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med: 2007; 356 2271 2281 (Pubitemid 46849157)
27. Johnston O, Rose CL, Webster AC et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol: 2008; 19 1411 1418
28. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation: 2001; 72 1181 1193 (Pubitemid 33026593)
29. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation: 2005; 80 883 889 (Pubitemid 41552882)
30. Kidney Disease: Improving Global Outcomes (KDIGO), Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant: 2009; 9 (03) S1 S157
31. Kraus-Zatecky A. Consensus Meeting Therapie nierentransplantierter Patienten mit Rapamune (Sirolimus). Dialyse Aktuell: 2001; 8 68 69
32. Kuypers DR. Benefit-risk-assessment of sirolimus in renal transplantation. Drug Safety: 2005; 28 153 181
33. Lebranchu Y, Thierry A, Toupance O et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant: 2009; 9 1115 1131
34. Letavernier E, Bruneval P, Mandet C et al. High Sirolimus Levels May Induce Focal Segmental Glomerulosclerosis De Novo. Clin J Am Soc Nephrol: 2007; 2 326 333
35. Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation: 2002; 73 1565 1572 (Pubitemid 34568667)
36. Mah E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation: 2005; 79 476 482 (Pubitemid 40280181)
37. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant: 2004; 8 446 449 (Pubitemid 39077081)
38. Morath C, Schwenger V, Ksoll-Rudek D et al. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transplant Proc: 2007; 39 99 102 (Pubitemid 46175977)
39. Motzer RJ, Escudier B, Oudard S. for the RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet: 2008; 372 449 456
40. Mulay AV, Hussain N, Fergusson D et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant: 2005; 5 1748 1756 (Pubitemid 40910459)
41. Nankivell BJ, Borrows RJ, Fung CLS et al. The natural history of chronic allograft nephropathy. N Engl J Med: 2003; 349 2326 2333 (Pubitemid 37509740)
42. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int: 2005; 18 22 28 (Pubitemid 41742941)
43. Peddi VR et al. An open-label pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant: 2005; 19 130 136 (Pubitemid 40227864)
44. Ruiz JC, Campistol JM, Sanchez-Fructuoso A et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant: 2006; 21 3252 3257 (Pubitemid 44567102)
45. Russ G, Campbell S, Walker R G et al. Kidney Transplant recipients at high risk for non-melanoma skin cancer (NMSC) may benefit from conversion to sirolimus versus continuation of calcineurin inhibitors. ASN: 2009; Abstract book [SA-FC350]
46. Russ G, Segoloni G, Oberbauer R. et al. for the Rapamune Maintenance Regimen Study Group Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation: 2005; 80 1204 1211 (Pubitemid 41746798)
47. Salgo R, Gossmann J, Schfer H et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant: 2010; 10 1385 1393
48. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation: 2009; 87 233 242
49. Schilke R. Aktualisierte Consensus-Empfehlungen zur Umstellung nierentransplantierter Patienten auf Rapamune. Medizinisch Juristische Nachrichten: 2002; 4 32 34
50. Schmid RW, Lotz J, Schweigert R et al. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin Biochem: 2009; 42 1543 1548
51. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposis sarcoma in renal transplant recipients. N Engl J Med: 2005; 352 1317 1323 (Pubitemid 40411498)
52. Steigerwalt SP, Brar N, Dhungel A et al. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients. Transplant Proc: 2009; 41 4184 4187
53. Trk TR, Witzke O, Zeier M. KDIGO-Leitlinien zur Betreuung von Nierentransplantatempfngern Deutsche bersetzung. Nephrologe: 2010; 5 94 107
54. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant: 2003; 3 1128 1134 (Pubitemid 37064553)
55. Wali RK, Drachenberg C, Hirsch HH et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation: 2004; 78 1069 1073 (Pubitemid 39391872)
56. Watson CJ, Firth J, Williams PF et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant: 2005; 5 2496 2503
57. Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation: 2006; 81 1234 1248
58. Weir M et al. Mycophenolate Mofetil/Sirolimus Maintenance Therapy after Calcineurin Inhibitor Withdrawal in Renal Transplant Recipients: 2-Year Outcomes of the Spare-the-Nephron (STN) Trial. Abstract# 33. Am J Transplant: 2009; 5 200
59. Weir M, Diekmann F, Flechner SM et al. mTOR inhibition: the learning curve in kidney. Transplantation. Transplant Int: 2010; 23 447 460
60. Wimmer CD, Rentsch M, Crispin A et al. The janus face of immunosuppression de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int: 2007; 71 1271 1278 (Pubitemid 46887541)
61. Yardimci N, Colak T, Sevmis S et al. Neurologic complications after renal transplant. Exp Clin Transplant: 2008; 6 224 228
62. Zuber J, Anglicheau D, Elie C et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant: 2008; 8 1471 1479 (Pubitemid 351989493)